Announcement time of this financial report: 2023-10-27 18:59:08

Eling Pharmaceutical (stock code: 002603) is a pharmaceutical industry company focusing on the field of traditional Chinese medicine. In recent years, China has vigorously developed the traditional Chinese medicine business and promoted the reform and development of traditional Chinese medicine. Ling Pharmaceutical has responded positively to national policies, is committed to R&D and innovation in traditional Chinese medicine, and promoted the upgrading and development of the traditional Chinese medicine industry.

In terms of assets and liabilities, Eling Pharmaceutical's total assets for the third quarter of 2023 were 17.435 billion yuan, up from 16.338 billion yuan at the end of the previous year. Total liabilities were $5.587 billion, slightly higher than $5.408 billion at the end of the previous year. The company's net assets were 11.848 billion yuan, up from 10.93 billion yuan at the end of the previous year. The balance ratio was 32.04%, down from 33.1% at the end of the previous year.

In terms of profit, Eling Pharmaceutical's operating income for the third quarter of 2023 was 8.575 billion yuan, up from 7.946 billion yuan in the same period last year. Operating profit was $2.129 billion, up from $1,756 billion in the same period last year. Net profit was $1,754 million, up from $1,412 million in the same period last year. However, gross margin and net profit margin were 61.01% and 20.45% respectively, both lower than 62.04% and 17.77% in the same period last year.

In terms of cash flow, Eling Pharmaceutical's net cash flow from operating activities in the third quarter of 2023 was 145 million yuan, a sharp decline from 1,224 billion yuan in the same period last year. The total cash inflow from operating activities was $7.664 billion, slightly lower than $7.82 billion for the same period last year. The total cash outflow from operating activities was $7.52 billion, up from $6,596 billion in the same period last year.

In summary, Eling Pharmaceutical's operating conditions in the third quarter of 2023 were generally stable, its balance and liability conditions were good, and profits continued to grow, but net cash flow declined sharply. Investors should pay attention to the company's cash flow situation, as well as its development strategy and market competition in the traditional Chinese medicine industry.

This article only represents the judgments made by analysts themselves or analysts based on AI analysis. It cannot be used as an investment indicator, nor does it constitute any investment advice. The original purpose of this article was to help investors analyze and judge capital market data in the most intuitive and fastest way and from the most professional perspective.